Vita Life SciencesASX:VLS -2.00%83 Return-on-Tangible-Equity is 20.55% as of Dec. 2025, which is 9% above its 10-year median of 18.80. GuruFocus rates ASX:VLS with a GF Score™ of 83/100 and a GF Value™ of A$2.48 (Fairly Valued). The stock has 1 warning sign investors should review. Among 896 Drug Manufacturers companies, Vita Life Sciences ranks better than 78.57% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Vita Life Sciences's annualized net income for the quarter that ended in Dec. 2025 was A$11.19 Mil. Vita Life Sciences's average shareholder tangible equity for the quarter that ended in Dec. 2025 was A$54.45 Mil. Therefore, Vita Life Sciences's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 20.55%.
The historical rank and industry rank for Vita Life Sciences's Return-on-Tangible-Equity or its related term are showing as below:
ASX:VLS'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 10.38 Med: 18.8 Max: 29.9
Current: 19.42
During the past 13 years, Vita Life Sciences's highest Return-on-Tangible-Equity was 29.90%. The lowest was 10.38%. And the median was 18.80%.
ASX:VLS's Return-on-Tangible-Equity is ranked better than 78.57% of 896
companies
in the Drug Manufacturers industry
Industry Median: 7.795
vs ASX:VLS: 19.42
Vita Life Sciences (ASX:VLS) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Vita Life Sciences Return-on-Tangible-Equity Related Terms
Vita Life Sciences Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Vita Life Sciences's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vita Life Sciences Return-on-Tangible-Equity Chart
ASX:VLS vs ZTS: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vita Life Sciences Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Vita Life Sciences's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 20.55% mean?
Vita Life Sciences (ASX:VLS) has a Return-on-Tangible-Equity of 20.55% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Vita Life Sciences and its competitors. This is near median its historical median of 18.80. Over the past decade, Vita Life Sciences' Return-on-Tangible-Equity has ranged from 10.38 to 29.90. According to the industry distribution chart, Vita Life Sciences ranks #192 out of 896 companies in the Drug Manufacturers industry, placing it in the top 21.4%.
Is Vita Life Sciences' Return-on-Tangible-Equity too high?
Vita Life Sciences' current Return-on-Tangible-Equity of 20.55% is near median its 10-year median of 18.80. Over the past 10 years, this metric has ranged from a low of 10.38 to a high of 29.90. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.80. Vita Life Sciences' value of 20.55% is 163.6% above this industry median. Based on the distribution chart, Vita Life Sciences ranks #192 out of 896 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vita Life Sciences has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' Return-on-Tangible-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vita Life Sciences ranks #192 out of 896 companies for Return-on-Tangible-Equity. This places Vita Life Sciences in the top 21% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 7.80. Vita Life Sciences' value of 20.55% is 163.6% above this benchmark. Historically, Vita Life Sciences' own Return-on-Tangible-Equity has ranged from 10.38 to 29.90 over the past decade. While the company's 10-year median is 18.80 vs. the industry median of 7.80, Vita Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.80, based on 896 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vita Life Sciences's current Return-on-Tangible-Equity of 20.55% is 163.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Vita Life Sciences and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vita Life Sciences's current Return-on-Tangible-Equity is 20.55%, which is near median its own 10-year median of 18.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.48, compared to a current price of A$2.45 — trading 1.2% below its estimated fair value. The current Return-on-Tangible-Equity is 20.55%, which is near median its 10-year median of 18.80 and 163.6% above the Drug Manufacturers industry median of 7.80. Vita Life Sciences' overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current Return-on-Tangible-Equity is 20.55% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?
Based on GuruFocus' analysis, Vita Life Sciences stock appears to be undervalued.
The current stock price of A$2.45 is trading 1.2% below its estimated GF Value™ of A$2.48.
GuruFocus considers Vita Life Sciences to be Fairly Valued.
Key valuation signals for ASX:VLS:
Return-on-Tangible-Equity: 20.55% (near median its 10-year median of 18.80)
GF Value™: A$2.48 vs. price of A$2.45 (1.2% below fair value)
Industry Position: 163.6% above the Drug Manufacturers median (#192 of 896)
No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
83GF Score
Get the complete analysis for ASX:VLS
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VLS has been successfully added to your 
